Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Table 6 Total arsenic concentrations in HMW-F and LMW-F of PB and BM plasma collected during the remission induction therapy

Clinical samples		PB					BM
Days after the start of administration		-1	14	28	42	56	-1	14	28	42	56
Arsenic concentrations (ngAs/g)	Total plasma	5.55	47.6	56.6	55.5	18.5	7.59	53.5	72.1	88.1	20.4
	HMW-F of plasma	1.31	20.1	25.0	27.7	9.98	1.77	26.3	44.2	62.9	14.4
	LMW-F of plasma	4.24	27.5	31.5	27.8	8.54	5.83	27.3	27.9	25.2	5.99

PB and BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. The total arsenic concentrations of HMW-F of PB and BM were determined by ICP-MS as described in "Patient and Methods". The total arsenic concentrations in LMW-F of PB and BM plasma were obtained by subtraction of that in HMW-F from the total arsenic concentrations in PB and BM plasma.